Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login


The Cancer Letter Inc.
PO Box 9905
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Feb 29, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Gilotrif Improves PFS Compared to Iressa in Phase IIb Trial in Non-Small Cell Lung Cancer


Results of the LUX-Lung 7 trial met two of its co-primary endpoints, in progression-free survival and time to treatment failure, with EGFR-directed therapy Gilotrif (afatinib) compared to Iressa (gefitinib) in the first-line treatment of patients with advanced non-small cell lung cancer.

The phase IIb trial results were presented at the 14th Annual British Thoracic Oncology Group Conference in Dublin. Data for the third co-primary endpoint, overall survival are not yet mature. The trial included 319 patients with advanced stage NSCLC harboring EGFR mutations del19 or L858R.

To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.